Article
Urology & Nephrology
K. Stinesen Kollberg, E. Holmberg, A. Josefsson, J. Hugosson, R. Arnsrud Godtman
Summary: The aim of this study was to describe the level of pre-testing and contamination in the Goteborg-1 prostate cancer screening trial. The results showed that similar proportions of men were prostate specific antigen-tested in both the screening group and control group, yet only a minority of contamination prostate specific antigens led to biopsy. Organized screening was found to be more effective in reducing prostate cancer mortality than non-organized testing.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Sebastiaan Remmers, Chris H. Bangma, Rebecka A. Godtman, Sigrid. Carlsson, Anssi Auvinen, Teuvo L. J. Tammela, Louis J. Denis, Vera Nelen, Arnauld Villers, Xavier Rebillard, Maciej Kwiatkowski, Franz Recker, Stephen Wyler, Marco Zappa, Donella Puliti, Giuseppe Gorini, Alvaro Paez, Marcos Lujan, Daan Nieboer, Fritz H. Schroeder, Monique J. Roobol
Summary: Based on the guidelines of the European Association of Urology, a risk-based strategy for prostate cancer screening should be determined by the first prostate-specific antigen (PSA) level and age. In this study, the baseline PSA level was found to guide decisions on the repeat screening interval and had an impact on prostate cancer detection and specific mortality rates.
Article
Urology & Nephrology
Patrick-Julien Treacy, Ugo G. Falagario, Francois Magniez, Parita Ratnani, Ethan Wajswol, Alberto Martini, Ivan Jambor, Peter Wiklund, Imad Bentellis, Flora Barthe, Natasha Kyprianou, Matthieu Durand, Daniel Steffens, Sascha Karunaratne, Scott Leslie, Ruban Thanigasalam, Ash Tewari
Summary: This study aimed to evaluate the genomic risk of patients with persistent prostate specific antigen (PSA) using mRNA expression analysis and a validated prognostic genomic-risk classifier. The findings revealed unique genomic features of patients with persistent PSA and confirmed that this condition is associated with a worse prognosis.
MINERVA UROLOGY AND NEPHROLOGY
(2023)
Article
Urology & Nephrology
Furkan Dursun, Chen-Pin Wang, Daniel MacCarthy, Ahmed M. Mansour, Deepak K. Pruthi, Dharam Kaushik, Ian M. Thompson, Michael A. Liss
Summary: The purpose of this study was to determine if the absolute PSA value after 6 months of ADT is predictive of survival in patients with prostate adenocarcinoma. The results showed that patients with high and intermediate PSA values had a higher risk of PCSM and all-cause mortality compared to those with low PSA values. This measure can be used to rapidly assess the efficacy of new interventions in clinical trials.
JOURNAL OF UROLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Pierre Olivier, Anne-Laure Giraudet, Andrea Skanjeti, Charles Merlin, Pierre Weinmann, Ines Rudolph, Alexander Hoepping, Mathieu Gauthe
Summary: The study aimed to compare F-18-PSMA-1007 PET/CT and 18F-fluorocholine PET/CT for localizing prostate cancer recurrence. The results showed that F-18-PSMA-1007 PET/CT was superior to 18F-fluorocholine PET/CT in localizing prostate cancer recurrence. Decision making based on F-18-PSMA-1007 PET/CT results was more beneficial.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Andrology
Jeong Hoon Oh, Ho Seok Chung, Myung Soo Kim, Eu Chang Hwang, Seung Il Jung, Dongdeuk Kwon, Kwangsung Park
Summary: PSA parameters have a similar diagnostic value in predicting prostate cancer in men with gray-zone PSA levels regardless of testosterone levels.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2022)
Article
Urology & Nephrology
Ivo I. de Vos, Annick Meertens, Renee Hogenhout, Sebastiaan Remmers, Monique J. Roobol
Summary: This study concludes that PSA-based screening for prostate cancer can reduce metastasis and mortality. The longer the follow-up, the greater the reduction in deaths and metastasis. The study also suggests that starting screening between the ages of 70 and 74 is not effective and repeated screenings are necessary.
Article
Urology & Nephrology
Molly E. DeWitt-Foy, Kristina Gam, Charles Modlin, Simon P. Kim, Robert Abouassaly
Summary: The study aimed to examine racial disparities in decisional regret among African American men with prostate cancer. Findings revealed that African American men experienced higher levels of decisional regret, partially explained by medical mistrust and concerns about masculinity.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Kendrick Yim, Chaoran Ma, Sigrid Carlsson, Hans Lilja, Lorelei Mucci, Kathryn Penney, Adam S. Kibel, Scott Eggener, Mark A. Preston
Summary: Adding percent free PSA to total PSA improved prediction of clinically significant prostate cancer and fatal prostate cancer. Free PSA can be used to stratify risk in screening and reduce unnecessary prostate biopsies.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Tarik Benidir, Ethan Austhof, Ryan D. D. Ward, Justin Ream, Jenifer Bullen, Baris Turkbey, Peter A. A. Pinto, Francesco Giganti, Eric A. A. Klein, Andrei S. S. Purysko
Summary: The study aimed to evaluate the impact of UroLift on prostate magnetic resonance imaging (MRI) quality. The results showed that UroLift has a negative impact on MRI quality, particularly in the mid-basal region, obscuring a significant portion of the prostate on diffusion-weighted images.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Michael S. Leapman, Kimberly Stone, Roxanne Wadia, Lesley S. Park, Cynthia L. Gibert, Matthew B. Goetz, Roger Bedimo, Maria Rodriguez-Barradas, Fatma Shebl, Amy C. Justice, Sheldon T. Brown, Kristina Crothers, Keith M. Sigel
Summary: The risk of prostate cancer among individuals living with human immunodeficiency virus (HIV) is not well understood. This study found that when accounting for less prostate-specific antigen (PSA) testing among HIV-positive individuals, the incidence of prostate cancer was similar to that of HIV-negative individuals.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Maha Hussain, Cora N. Sternberg, Eleni Efstathiou, Karim Fizazi, Qi Shen, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Ugo De Giorgi, Neal D. Shore, Fred Saad
Summary: This study analyzed the relationship between depth of PSA decline and clinical outcomes in men with nonmetastatic castration-resistant prostate cancer. The results showed that greater depth of PSA decline was associated with improved metastasis-free survival and overall survival, suggesting a previously underestimated relationship between changes in PSA levels and clinical outcomes.
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Jonathan Harper, Trevor Hunt, Mouneeb Choudry, Ashley L. Kapron, Kathleen A. Cooney, Christopher Martin, Jacob Ambrose, Brock O'Neil
Summary: This study aimed to evaluate the interest of primary care clinicians in utilizing clinical decision support (CDS) for prostate-specific antigen (PSA) screening. The results showed that all surveyed clinicians were interested in CDS, regardless of their current screening practices. Clinicians generally agreed that CDS should be evidence-based, but disagreed on whether it would decrease professional discretion over patient decisions.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Multidisciplinary Sciences
Libin Nan, Kai Guo, Mingmin Li, Qi Wu, Shaojun Huo
Summary: A nomogram prediction model for prostate cancer was developed using clinical data, and compared with other prediction models. The results showed that the model had higher predictive value, and could be used to assess the probability of prostate cancer and guide prostate biopsy.
Article
Oncology
Otis L. Owens, Robin M. Dawson, Tracey Thomas
Summary: This study explores the role of emotions in prostate cancer treatment decisions, highlighting five key variables that impact decision-making: age, spirituality, family support, healthcare provider communication, and perception of treatment outcomes. The findings suggest healthcare providers play a significant role in guiding treatment decisions by taking into account these variables.
Article
Urology & Nephrology
Renee Hogenhout, Daniel F. Osses, Arnout R. Alberts, Hanne G. Buizer-Rijksen, Sebastiaan Remmers, Monique J. Roobol
Summary: This study aimed to evaluate the feasibility of multivariable risk stratification for early prostate cancer detection. The results showed that using the Rotterdam Prostate Cancer Risk Calculator (RPCRC) in a primary healthcare diagnostic facility could reduce up to 68% of referrals compared to a PSA threshold of 3.0 ng/mL, while maintaining a high detection rate of clinically significant prostate cancer.
Article
Oncology
Renee Hogenhout, Sebastiaan Remmers, Geert J. L. H. van Leenders, Monique J. Roobol
Summary: TPB has no different csPCa detection rate from TRB taking CR/IDC into account. TPB is, however, preferable because of less infectious complications, even if AP is omitted.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Urology & Nephrology
Ivo I. de Vos, Annick Meertens, Renee Hogenhout, Sebastiaan Remmers, Monique J. Roobol
Summary: This study concludes that PSA-based screening for prostate cancer can reduce metastasis and mortality. The longer the follow-up, the greater the reduction in deaths and metastasis. The study also suggests that starting screening between the ages of 70 and 74 is not effective and repeated screenings are necessary.
Article
Cell Biology
Margaretha A. van Der Slot, Sebastiaan Remmers, Charlotte F. Kweldam, Michael A. den Bakker, Daan Nieboer, Martijn B. Busstra, Melanie Gan, Sjoerd Klaver, John B. W. Rietbergen, Geert J. L. H. van Leenders
Summary: Ipsilateral perineural invasion (PNI) and percentage of positive cores are significant predictors for positive posterolateral surgical margins in men undergoing bilateral nerve-sparing radical prostatectomy.
Article
Urology & Nephrology
Muhammad Imran Omar, Steven MacLennan, Maria J. Ribal, Monique J. Roobol, Konstantinos Dimitropoulos, Thomas van den Broeck, Sara J. MacLennan, Susan Evans Axelsson, Giorgio Gandaglia, Peter-Paul Willemse, Ken Mastris, John Butler Ransohoff, Zsuzsanna Devecseri, Thomas Abbott, Bertrand De Meulder, Anders Bjartell, Alex Asiimwe, James N'Dow, Emma Smith, Karin Plass, Nicolas Mottet, Robert Shepherd, Lisa Moris, Michael Lardas, Nicola Fossati, Karl Pang, Riccardo Campi, Isabella Greco, Mauro Gacci, Sergio Serni, Ragnar Lonnerbro, Alberto Briganti, Daniele Crosti, Roberto Garzonio, Martina Faticoni, Chris Bangma, Eliza Roest, Arjan Breederland, Sebastiaan Remmers, Derya Tilki, Anssi Auvinen, Teemu Murtola, Tapio Visakorpi, Kirsi Talala, Teuvo Tammela, Aino Siltari, Mieke Van Hemelrijck, Katharina Beyer, Stephane Lejeune, Laurence Colette, Simona Caputova, Delielena Poli, Sigrid van Dorp, Sophie Byrne, Luz Fialho, Ashley Rowland, Neo Tapela, Francesco Ugolini, Charles Auffray, Nesrine Taibi, Ayman Hijazy, Albert Saporta, Kai Sun, Shaun Power, Nazanin Zounemat Kermani, Kees van Bochove, Maxim Moinat, Mirella Kalafati, Azadeh Tafreshiha, Chiara Bernini, Kristina Hlavati, Denis Horgan, Louise Fullwood, Marc Holtorf, Doron Lancet, Gabi Bernstein, Sheela Tripathee, Manfred Wirth, Michael Froehner, Beate Brenner, Angelika Borkowetz, Christian Thomas, Friedemann Horn, Kristin Reiche, Markus Kreuz, Andreas Josefsson, Delila Gasi Tandefelt, Jonas Hugosson, Jack Schalken, Henkjan Huisman, Thomas Hofmarcher, Peter Lindgren, Emelie Andersson, Adam Fridhammar, Monica Tames Grijalva, Frank Verholen, Jihong Zong, Todd Williamson, Kumari Chandrawansa, Reg Waldeck, Amanda Bruno, Ronald Herrera, Ekaterina Nevedomskaya, Samuel Fatoba, Niculae Constantinovici, Ateesha Mohamed, Carl Steinbeisser, Monika Maass, Patrizia Torremante, Emmanuelle Dochy, Federica Pisa, Marc Dietrich Voss, Amit Kiran, Kishore Papineni, Jing Wang-silvanto, Robert Snijder, Xuewei Wang, Mark Lambrecht, Russ Wolfinger, Laurent Antoni, Angela Servan, Katie Pascoe, Paul Robinson, Bertrand Jaton, Daniel Bakkard, Heidi Turunen, Olavi Kilkku, Pasi Pohjanjousi, Olli Voima, Liina Nevalaita, Keijo Punakivi, Christian Reich, Sarah Seager, Shilpa Ratwani, Elaine Longden-Chapman, Danny Burke, Muriel Licour, Sarah Payne, Alan Yong, Flavia Lujan, Sophia Le Mare, Jan Hendrich, Michael Bussmann, Guido Juckeland, Daniel Kotik
Summary: In this study, an international consensus was conducted to identify the most important questions in the field of prostate cancer that could be addressed using big data. A modified Delphi survey was conducted to gather opinions from healthcare professionals and patients, aiming to understand the critical impact of answering these questions on diagnosis and treatment outcomes for prostate cancer patients.
NATURE REVIEWS UROLOGY
(2023)
Article
Oncology
Benjamin E. White, Beth Russell, Sebastiaan Remmers, Brian Rous, Kandiah Chandrakumaran, Kwok F. Wong, Mieke Van Hemelrijck, Rajaventhan Srirajaskanthan, John K. Ramage
Summary: This retrospective, population-based study compared overall survival (OS) between males and females with neuroendocrine neoplasia (NEN). The study found that females had higher survival rates regardless of tumor stage, morphology, or level of deprivation, especially in NEN of the lung, pancreas, rectum, and stomach. The stage of tumor mediated improved survival in certain types of NEN but not in rectal NEN. Future research and treatment should consider sex as an important factor.
Review
Andrology
Katharina Beyer, Sebastiaan Remmers, Mieke Van Hemelrijck, Monique J. Roobol, Lionne D. F. Venderbos
Summary: This article examines the impact of health literacy on the choice and adherence to active surveillance (AS) through a literature review. The findings suggest that lower health literacy negatively affects patients' decision-making and adherence to treatment, while interventions targeting health literacy have a positive impact on these aspects.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2023)
Article
Urology & Nephrology
Petter Davik, Sebastiaan Remmers, Mattijs Elschot, Monique J. Roobol, Tone Frost Bathen, Helena Bertilsson
Summary: This study compared the performance of available biopsy decision support tools incorporating magnetic resonance imaging (MRI) findings in predicting clinically significant prostate cancer in a high-risk cohort. The results showed that multivariable MRI risk calculators outperformed and should be favored over decision strategies based only on MRI and prostate-specific antigen density.
Article
Medicine, General & Internal
Ugo Giovanni Falagario, Ahmad Abbadi, Sebastiaan Remmers, Lars Bjornebo, Darko Bogdanovic, Alberto Martini, Alexander Valdman, Giuseppe Carrieri, Mani Menon, Olof Akre, Martin Eklund, Tobias Nordstrom, Henrik Gronberg, Anna Lantz, Peter Wiklund
Summary: This study aimed to evaluate the association between biochemical recurrence (BCR) and prostate cancer-specific mortality (PCSM) after radical prostatectomy or radiotherapy, as well as the current risk stratification. The findings suggest that low-risk patients after radiotherapy have a low risk of PCSM, while low-risk patients after radical prostatectomy have a relatively higher risk of PCSM.
Article
Urology & Nephrology
Sebastiaan Remmers, Daan Nieboer, Monique J. Roobol
Summary: The study in the Netherlands found that PSA-based screening can lead to earlier detection of prostate cancer, but it can also result in a reduction in quality of life due to earlier treatment.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
Review
Andrology
Katharina Beyer, Sebastiaan Remmers, Mieke Van Hemelrijck, Monique J. Roobol, Lionne D. F. Venderbos
Summary: This study examined the impact of health literacy on choosing and adhering to active surveillance (AS) for prostate cancer patients. Results showed that the level of health literacy has an influence on patients' decision-making and adherence to AS. Interventions targeting health literacy have been found to improve treatment decision making and adherence.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2023)
Article
Urology & Nephrology
Marinus J. Hagens, Piter J. Stelwagen, Hans Veerman, Sybren P. Rynja, Martijn Smeenge, Vincent van der Noort, Ton A. Roeleveld, Jolien van Kesteren, Sebastiaan Remmers, Monique J. Roobol, Pim J. van Leeuwen, Henk G. van der Poel
Summary: The current study aimed to externally validate the Rotterdam Prostate Cancer Risk Calculator (RPCRC)-3/4 and RPCRC-MRI in a Dutch clinical cohort. The study found that RPCRC-3/4 underestimated the probability of clinically significant prostate cancer (csPCa) in this cohort, resulting in missed diagnoses. The recalibration and adjustment of risk thresholds improved the performance. RPCRC-MRI demonstrated good performance.
WORLD JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Sebastiaan Remmers, Jozien Helleman, Daan Nieboer, Bruce Trock, Matthew E. Hyndman, Caroline M. Moore, Vincent Gnanapragasam, Lui Shiong Lee, Oussama Elhage, Laurence Klotz, Peter Carroll, Tom Pickles, Anders Bjartell, Gregoire Robert, Mark Frydenberg, Mikio Sugimoto, Behfar Ehdaie, Todd M. Morgan, Jose Rubio-Briones, Axel Semjonow, Chris H. Bangma, Monique J. Roobol
Summary: The study found that there is no significant difference in the risk of disease progression during active surveillance between younger men and those with intermediate-risk disease compared to older men and those with low-risk disease. The proportion of adverse pathology was lower among younger men and those with low-risk disease.
EUROPEAN UROLOGY OPEN SCIENCE
(2022)
Article
Urology & Nephrology
Sebastiaan Remmers, Veeru Kasivisvanathan, Jan F. M. Verbeek, Caroline M. Moore, Monique J. Roobol
Summary: This study retrospectively assessed the use of the Rotterdam Prostate Cancer Risk Calculator in both a screening cohort and a clinical cohort. The results show that the calculator performed well, but recalibration and adaptation of the risk threshold are necessary for optimal performance.
EUROPEAN UROLOGY OPEN SCIENCE
(2022)
Article
Urology & Nephrology
Sebastiaan Remmers, Daan Nieboer, L. Lucia Rijstenberg, Tim Hansum, Geert J. L. H. van Leenders, Monique J. Roobol
Summary: The Rotterdam Prostate Cancer Risk Calculator (RPCRC) is a validated tool for risk stratification, helping reduce the number of prostate biopsies and MRI scans. By updating the RPCRC, men with previous negative biopsies but presence of invasive cribriform and/or intraductal carcinoma can be effectively identified.
EUROPEAN UROLOGY OPEN SCIENCE
(2022)